Currently out of the existing stock ratings of Yaron Werber, 79 are a BUY (71.17%), 31 are a HOLD (27.93%), 1 are a SELL (0.9%).

Yaron Werber

Work Performance Price Targets & Ratings Chart

Analyst Yaron Werber, currently employed at TD COWEN, carries an average stock price target met ratio of 70.9% that have a potential upside of 24.02% achieved within 417 days. Previously, Yaron Werber worked at COWEN.

Yaron Werber’s has documented 211 price targets and ratings displayed on 27 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on EXEL, Exelixis at 13-May-2025.

Wall Street Analyst Yaron Werber

Analyst best performing recommendations are on ARGX (ARGENX NV ADR).
The best stock recommendation documented was for ARGX (ARGENX NV ADR) at 7/17/2023. The price target of $533 was fulfilled within 3 days with a profit of $48.57 (10.03%) receiving and performance score of 33.42.

Average potential price target upside

of $91.76 (22.98%) on ARGX (ARGENX NV ADR).
of $71.7 (48.15%) on AMGN (AMGEN).
of $52.7 (10.84%) on REGN (REGENERON PHARMACEUTICALS).

AMGN Amgen ARGX argenx NV ADR BGNE BeiGene Ltd FGEN FibroGen RARE Ultragenyx XLRN Acceleron Pharma BLUE Bluebird bio EPZM Epizyme REGN Regeneron Pharmaceuticals ASND Ascendis Pharma AS ROIV Roivant Sciences Ltd TIL Instil Bio TSVT 2Seventy Bio EXEL Exelixis BNTX BioNTech SE GILD Gilead Sciences IOBT IO Biotech GBIO Generation Bio Co ORTX Orchard Therapeutics PLC GMAB Genmab AS IONS Ionis Pharmaceuticals LEGN Legend Biotech Corp STOK Stoke Therapeutics CELG Celgene COGT Cogent Biosciences PRVL Prevail Therapeutics SWTX SpringWorks Therapeutics

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Tim Anderson (BAML)